CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are ...
Montreal, Quebec, Canada
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Montreal, Quebec, Canada and 71 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Saint-Jérôme, Quebec, Canada and 319 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Montreal, Canada and 144 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Montreal, Quebec, Canada and 37 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Montreal, Quebec, Canada and 28 other locations
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-...
Phase 3
Montreal, Quebec, Canada and 257 other locations
with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...
Phase 3
Montreal, Quebec, Canada and 166 other locations
+/HER2-) advanced breast cancer....
Phase 1, Phase 2
Montreal, Quebec, Canada and 32 other locations
versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane....
Phase 3
Montreal, Quebec, Canada and 163 other locations
Clinical trials
Research sites
Resources
Legal